Pfizer Recalls Nurtec ODT Prescription Drugs Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning
Source: CPSC Recall #23154
Recall Date
2023-03-16
Manufacturer
Biohaven Pharmaceuticals Inc., of New Haven, Conn., Pfizer Inc., of New York
Units Affected
About 4.2 million
Products Involved
Nurtec® ODT (rimegepant) orally disintegrating tablets, 75mg 8-Unit Dose blister pack
Hazard
The recalled prescription drugs must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children.
Remedy
Consumers should immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child resistant pouch to store the product. Once the product is secured, consumers can continue to use it as directed.
Reported Injuries
None reported
Sold At
Pharmacies nationwide as a prescribed medicine from December 2021 through March 2023. The prices of the product varied based on health insurance terms and other factors.
Manufactured In
United States
Full Recall Description
This recall involves prescription drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets. The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, expiration date. The dosage strength and expiration date are printed or stamped on the blister card. The recall includes the following: Product Description NDC Number Expiration Date Nurtec® ODT (rimegepant) 75mg 8-Unit Dose blister pack 72618-3000-2 All dates through 6/2026
Data source: U.S. Consumer Product Safety Commission (CPSC) via SaferProducts.gov.
For the most current recall information, check directly with CPSC or the manufacturer.
Last verified: 2026-03-28